美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Talazoparib Tosylate	Capsule	II (Paddle) with sinker	75	0.01 N HCl with 0.2% sodium dodecyl sulfate (SDS),	500	10, 15, 20, 30 and 45	2020/08/27
Tamoxifen Citrate	Tablet			Refer to USP			2009/04/02
Tamsulosin HCl	Capsule	II (Paddle)	100	0-2 hours: 0.003% polysorbate 80, pH 1.2 2-8 hours: phosphate buffer, pH 7.2	500	1, 2, 3, 6, 8, and 10 hours	2007/03/26
Tapentadol HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tapentadol HCl	Tablet (Extended Release)	II (Paddle) with sinker	100	0.05 M Phosphate Buffer of pH 6.8, Simulated intestinal fluid (without enzyme)	900	0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours	2013/10/31
Tasimelteon	Suspension			Refer to FDA's Dissolution Guidance, 2018			2024/05/31
Tasimelteon	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tazemetostat Hydrobromide	Tablet	II (Paddle)	50	0.01 N HCl	900	5, 10, 15, 20, 30 and 45	2022/05/12
Tedizolid Phosphate	Tablet	II (Paddle)	60	0.05 M phosphate buffer pH 6.8	900	5, 10, 15, 20 and 30	2016/06/02
Tegaserod Maleate	Tablet			Develop a dissolution method			2023/09/15
Telaprevir	Tablet			Develop a dissolution method			2023/09/15
Telbivudine	Tablet	II (Paddle)	50	0.1 N HCl	900	15, 30 and 45	2009/04/02
Telithromycin	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 20, 30 and 45	2007/01/03
Telmisartan	Tablet			Refer to USP			2012/01/05
Temazepam	Capsule			Refer to USP			2008/01/14
Temozolomide	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tenapanor Hydrochloride	Tablet	II (Paddle)	75	9.4 mM Citrate Buffer, pH 4	900	5, 10, 15, 20, 30 and 45	2021/08/19
Tenofovir Alafenamide Fumarate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tenofovir Disoproxil Fumarate	Powder for Oral	II (Paddle)	100	0.2% polysorbate 80 in 0.01 M HCl	900	10, 20, 30, 45, 60 and 75	2013/01/31
Tenofovir Disoproxil Fumarate	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 20, 30, and 45	2007/01/03